ArticleJournal of biochemical and molecular toxicology2026
Tumor-Associated Mast Cells Drive Immunosuppression and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4-mediated Regulatory T-Cell Recruitment.
Article in Journal of biochemical and molecular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated how tumor-associated mast cells (TAMCs) contribute to immunosuppression and anti-PD-1 resistance in hepatocellular carcinoma (HCC). TAMC infiltration as well as the levels of stem cell factor (SCF) and various chemokines were measured in clinical specimens obtained from 59 HCC patients. The recruitment and maintenance of TAMCs by HCC-conditioned medium were examined, with a focus on the role of SCF in these processes. In addition, the chemotactic effect of CCL17 (secreted by activated TAMCs) on CCR4-expressing regulatory T cells (Tregs) was evaluated. The functional impact of the recruited Tregs was further assessed by examining their capacity to inhibit the proliferation of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.